Victory Capital Management Inc. Has $29.14 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Victory Capital Management Inc. trimmed its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 17.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 255,040 shares of the company’s stock after selling 52,476 shares during the quarter. Victory Capital Management Inc. owned approximately 0.23% of Vaxcyte worth $29,143,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its position in Vaxcyte by 68.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock worth $2,453,000 after purchasing an additional 8,685 shares in the last quarter. Harbor Capital Advisors Inc. increased its position in Vaxcyte by 392.4% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company’s stock worth $3,046,000 after purchasing an additional 32,149 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Vaxcyte by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock worth $216,966,000 after purchasing an additional 498,359 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Vaxcyte during the 1st quarter worth approximately $1,288,000. Finally, Tri Locum Partners LP acquired a new position in Vaxcyte in the 2nd quarter valued at approximately $8,559,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Stock Performance

NASDAQ:PCVX opened at $86.83 on Monday. The firm’s fifty day moving average is $110.67 and its 200-day moving average is $88.83. Vaxcyte, Inc. has a 52 week low of $48.24 and a 52 week high of $121.06. The firm has a market cap of $10.82 billion, a P/E ratio of -18.88 and a beta of 1.01.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the business earned ($0.91) earnings per share. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total transaction of $538,350.00. Following the transaction, the senior vice president now directly owns 12,723 shares of the company’s stock, valued at $1,369,885.41. This represents a 28.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total transaction of $1,184,700.00. Following the transaction, the chief executive officer now owns 478,888 shares in the company, valued at approximately $37,822,574.24. The trade was a 3.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 117,464 shares of company stock valued at $12,640,276 over the last ninety days. 3.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Mizuho upped their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Jefferies Financial Group upped their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Bank of America upped their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Finally, BTIG Research upped their price target on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.